Table 3 Major adverse events (includes treatment-emergent adverse events)

From: Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis

Outcomes Number of studies Number of adverse events/participants I2 Risk ratio (RR) 95% CI P value
Galcanezumab Placebo
Injection-site pain 5 205/1579 149/1419 60% 1.43 0.99–2.06 0.04
Nasopharyngitis 5 106/1579 104/1419 19% 0.91 0.67–1.24 0.56
Upper respiratory tract infection 4 93/1153 55/987 0% 1.33 0.97–1.83 0.08
Injection-site erythema 4 54/1306 20/1275 0% 2.44 1.46–4.06 0.0006
Back pain 4 47/1125 36/958 15% 1.03 0.64–1.66 1.03
Sinusitis 4 39/1125 26/958 0% 1.33 0.81–2.19 0.26
Influenza 4 34/1472 23/1309 0% 1.36 0.79–2.33 0.26
Neck pain 4 21/1125 14/958 0% 1.27 0.64–2.53 0.49
Dizziness 3 31/987 24/1003 0% 1.31 0.77–2.22 0.32
Nausea 3 24/806 29/679 0% 0.74 0.43–1.27 0.27
Injection site pruritus 3 39/1199 2/1172 0% 13.42 3.70–48.62  < 0.0001
Injection site reaction 3 67/1199 14/1172 73% 4.87 1.20–19.85 0.03
Urinary tract infection 3 35/1018 23/848 0% 1.39 0.83–2.35 0.21
Abdominal pain 2 16/426 12/389 0% 1.21 0.58–2.55 0.61
Arthralgia 2 12/426 12/389 0% 0.95 0.43–2.09 0.90
Dysmenorrhea 2 12/699 2/569 0% 3.32 0.80–13.71 0.10
Migraine 2 16/745 9/711 0% 1.66 0.74–3.73 0.22
Oropharyngeal pain 2 14/745 6/711 0% 2.20 0.85–5.68 0.10
Weight increased 2 13/745 10/711 0% 1.23 0.54–2.80 0.63
Fatigue 2 23/773 22/740 0% 0.99 0.55–1.76 0.97
Diarrhea 2 19/773 20/740 0% 0.90 0.48–1.60 0.74
Bronchitis 2 15/699 6/569 0% 1.92 0.74–4.95 0.18
Rash 1 5/107 0/110 11.31 0.63–201.99 0.10
Hypertension 1 5/107 0/110 11.31 0.63–201.99 0.10
Pain in extremity 1 4/107 5/110 0.82 0.23–2.98 0.77
Toothache 1 4/107 1/110 4.11 0.47–36.20 0.20
Viral gastroenteritis 1 2/107 4/110 0.51 0.10–2.75 0.44
Cough 1 10/426 7/432 1.45 0.56–3.77 0.45
Pruritus 1 8/426 1/432 8.11 1.02–64.58 0.05
Injection site bruising 1 6/426 6/432 1.01 0.33–3.12 0.98
Nasal congestion 1 6/426 4/432 1.52 0.43–5.35 0.51
Vertigo 1 6/426 2/432 3.04 0.62–14.99 0.17
Contusion 1 5/426 5/432 1.01 0.30–3.48 0.98
Injection site swelling 1 6/454 0/461 13.20 0.75–233.63 0.08
Pyrexia 1 6/319 2/279 2.62 0.53–12.9 0.24
Pain in extremity 1 3/273 1/137 1.51 0.16–14.34 0.72